Literature DB >> 17637947

Increased risk of colorectal cancer in ulcerative colitis patients diagnosed after 40 years of age.

Constantine J Karvellas1, Richard N Fedorak, John Hanson, Clarence K W Wong.   

Abstract

BACKGROUND: The association between ulcerative colitis (UC) and colorectal cancer (CRC) is well established. Retrospective data show a 5.4% CRC incidence rate among patients with pancolitis and suggest that cancer surveillance should be provided to patients following eight to 10 years of extensive UC. AIM: To identify premalignant risk factors for UC patients and to determine whether current recommendations for cancer surveillance need reviewing. PATIENTS AND METHODS: A retrospective audit was conducted of adult patients with UC who were diagnosed with CRC between 1991 and 2002 in five hospitals in Edmonton, Alberta.
RESULTS: Thirty-one cases of CRC (68% male) were identified. In this group, the mean ages at diagnosis were 44.4 years for UC patients and 60.1 years for CRC patients. For patients in whom the initial data of diagnosis of UC could be determined (n=29), the median duration of UC at the time of CRC diagnosis was 16 years. Patients diagnosed with UC after 40 years of age (n=15, mean age 64 years) progressed more rapidly to CRC than patients diagnosed before 40 years of age (n=14, mean age 23 years). The median durations of UC before development of CRC were 22 years and 10 years, respectively, for patients with a diagnosis of UC before and after 40 years of age (OR 11.5, 95% CI 2.41 to 20.16; P=0.00029). Only four patients (13%) were enrolled in an appropriate cancer-screening program. Nine of these UC patients (29%) who were older than 40 years of age developed CRC before the 10-year point.
CONCLUSIONS: In the present study, patients diagnosed with UC after 40 years of age developed CRC more rapidly than those diagnosed before 40 years of age. This finding suggests that patients who are diagnosed with UC after 40 years of age should undergo CRC surveillance earlier than current recommendations.

Entities:  

Mesh:

Year:  2007        PMID: 17637947      PMCID: PMC2657965          DOI: 10.1155/2007/136406

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN: 0835-7900            Impact factor:   3.522


  24 in total

Review 1.  Ulcerative colitis-associated neoplasia.

Authors:  Shigehiko Fujii; Takahiro Fujimori; Hiroshi Kashida
Journal:  Pathol Int       Date:  2002-03       Impact factor: 2.534

2.  Stool-based DNA tests for colorectal cancer: clinical potential and early results.

Authors:  David A Ahlquist
Journal:  Rev Gastroenterol Disord       Date:  2002

3.  Colorectal cancer prevention in ulcerative colitis: a case-control study.

Authors:  J Eaden; K Abrams; A Ekbom; E Jackson; J Mayberry
Journal:  Aliment Pharmacol Ther       Date:  2000-02       Impact factor: 8.171

4.  Accelerated age-related CpG island methylation in ulcerative colitis.

Authors:  J P Issa; N Ahuja; M Toyota; M P Bronner; T A Brentnall
Journal:  Cancer Res       Date:  2001-05-01       Impact factor: 12.701

5.  Colorectal carcinoma in ulcerative colitis is decreasing in Scandinavian countries.

Authors:  C A Rubio; R Befrits; T Ljung; E Jaramillo; P Slezak
Journal:  Anticancer Res       Date:  2001 Jul-Aug       Impact factor: 2.480

6.  The risk of colorectal cancer in ulcerative colitis: a meta-analysis.

Authors:  J A Eaden; K R Abrams; J F Mayberry
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

7.  Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis.

Authors:  Ralf Kiesslich; Johannes Fritsch; Martin Holtmann; Heinz H Koehler; Manfred Stolte; Stephan Kanzler; Bernhard Nafe; Michael Jung; Peter R Galle; Markus F Neurath
Journal:  Gastroenterology       Date:  2003-04       Impact factor: 22.682

8.  Mesalazine-induced apoptosis of colorectal cancer: on the verge of a new chemopreventive era?

Authors:  P J Bus; I D Nagtegaal; H W Verspaget; C B Lamers; H Geldof; J H Van Krieken; G Griffioen
Journal:  Aliment Pharmacol Ther       Date:  1999-11       Impact factor: 8.171

Review 9.  Stool screening for colorectal cancer: evolution from occult blood to molecular markers.

Authors:  David A Ahlquist; Anthony P Shuber
Journal:  Clin Chim Acta       Date:  2002-01       Impact factor: 3.786

10.  Usefulness of analysis of p53 alteration and observation of surface microstructure for diagnosis of ulcerative colitis-associated colorectal neoplasia.

Authors:  S Fujii; T Fujimori; T Chiba
Journal:  J Exp Clin Cancer Res       Date:  2003-03
View more
  18 in total

Review 1.  Management of Ulcerative Colitis in the Elderly.

Authors:  Manish P Shrestha; Sasha Taleban
Journal:  Drugs Aging       Date:  2019-01       Impact factor: 3.923

2.  Predictors of aggressive inflammatory bowel disease.

Authors:  Andres J Yarur; Sebastian G Strobel; Amar R Deshpande; Maria T Abreu
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-10

Review 3.  Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies.

Authors:  Peter-Laszlo Lakatos; Laszlo Lakatos
Journal:  World J Gastroenterol       Date:  2008-07-07       Impact factor: 5.742

Review 4.  Colorectal cancer in inflammatory bowel disease: what is the real magnitude of the risk?

Authors:  Jessica K Dyson; Matthew D Rutter
Journal:  World J Gastroenterol       Date:  2012-08-07       Impact factor: 5.742

Review 5.  Clinical outcomes and management of inflammatory bowel disease in the older patient.

Authors:  Christina Y Ha; Seymour Katz
Journal:  Curr Gastroenterol Rep       Date:  2013-02

6.  Long-term follow-up reveals high incidence of colorectal cancer in Indian patients with inflammatory bowel disease.

Authors:  Sawan Bopanna; Saurabh Kedia; Prasenjit Das; S Dattagupta; V Sreenivas; V Pratap Mouli; Rajan Dhingra; Rajesh Pradhan; N Suraj Kumar; Dawesh P Yadav; Govind Makharia; Vineet Ahuja
Journal:  United European Gastroenterol J       Date:  2016-11-17       Impact factor: 4.623

7.  Cancer risk in chronic rhinosinusitis: a propensity score matched case-control cohort study.

Authors:  Chuan-Xin Xia; Yi-Wei Kao; Lei Qin; Ming-Chih Chen; Ben-Chang Shia; Szu-Yuan Wu
Journal:  Am J Transl Res       Date:  2019-11-15       Impact factor: 4.060

Review 8.  Tissue-resident cytotoxic innate lymphoid cells in tumor immunosurveillance.

Authors:  Efstathios G Stamatiades; Ming O Li
Journal:  Semin Immunol       Date:  2019-03-21       Impact factor: 11.130

9.  Fatty acid synthase inhibitor C75 ameliorates experimental colitis.

Authors:  Shingo Matsuo; Weng-Lang Yang; Monowar Aziz; Shingo Kameoka; Ping Wang
Journal:  Mol Med       Date:  2014-01-17       Impact factor: 6.354

10.  Immunohistochemical expression of proinflammatory enzyme COX-2 and p53 in ulcerative colitis and its associated dysplasia and colorectal carcinoma.

Authors:  Nehal Mohamed Elmashad; Dina H Ziada; Eiman A Hasby; Abd El Motaleb Mohamed
Journal:  J Microsc Ultrastruct       Date:  2016-03-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.